Johnson & Johnson to acquire Ambrx Biopharma, Inc. in a cash transaction
Mar 06, 2024•almost 2 years ago
Acquiring Company
Johnson & Johnson
Acquired Company
Ambrx
San DiegoBiopharmaTherapeuticsBiotechnologyHealth CareDescription
Ambrx Biopharma, Inc. shareholders have approved the acquisition proposal from Johnson & Johnson. Under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash upon the closing of the transaction. This acquisition is a strategic move for Johnson & Johnson to expand its portfolio in the field of antibody drug conjugates (ADCs) and other engineered therapies for cancer treatment.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed